Summary Rhizoxin is a new anti-tumour agent isolated from the pathogenic fungus Rhizopus chinensis. It has shown broad activity against murine tumour models and is also active against vinca alkaloid-resistant cells. 
Rhizoxin (NSC 332.598; E 87/010) is a macrocyclic lactone antibiotic with antifungal and antineoplastic activity isolated from the pathogenic fungus Rhizopus chinensis (Iwasaki et al., 1984 (Iwasaki et al., , 1986 Tsuruo et al., 1986) . A recognised mechanism of action for rhizoxin includes binding to the tubulin #-chain at a site that is different from the vinblastine or colchicine binding sites but apparently identical with the binding site of maytansin (Takahashi et al., 1987a (Takahashi et al., , 1989 Bai et al., 1990; Hamel, 1992) . Subsequently, polymerisation of tubulin is effectively inhibited and depolymerisation of microtubuli promoted (Takahashi et al., 1987b) . By this mechanism, rhizoxin inhibits mitosis and lacks cross-resistance with vincristine or vinblastine (Otake, 1988) . Rhizoxin has shown promising anti-tumour activity in a variety of experimental models in vitro and in vivo, including murine leukaemias, melanoma, sarcoma, breast, non-small and small-cell lung, colon and renal cancers (Kiyoto et al., 1986; Hendriks et al., 1992; Takigawa et al., 1993) . One clinical phase I trial has been completed and has shown a maximal tolerated dose of 2.6 mg m-2 when the agent was administered as intravenous infusion over 5 min repeated every 3 weeks. Dose-limiting toxicities were mucositis, diarrhoea, and myelotoxicity. Other side-effects included malaise and phlebitis at the injection site. Minor tumour regressions were seen in two patients with advanced breast cancer in one phase I trial. The recommended dose with this schedule was 2.0 mg m-2 (Bissett et al., 1992; Graham et al., 1992) .
In view of the preclinical data indicating the potential for broad-spectrum activity, a co-ordinated phase II programme studying a number of tumor types was planned, involving 
Patients and methods

Patients
Eligibility criteria for both studies included: histologically or cytologically confirmed disease; at least one bidimensionally measurable lesion; age >18 years; adequate bone marrow function (leucocytes >4000 pl-', platelets > 100 000 ,ul'-); adequate renal function (serum creatinine < 140 jmol 1-l or creatinine clearance >60 ml min-'; adequate liver function (serum bilirubin < 26 4umol I-1; SGPT and SGOT < three times the upper limit of normal); WHO performance status < 2; estimated life expectancy >3 months; no symptomatic brain or leptomeningeal disease; no other malignancies (exception: adequately treated cone-biopsied in situ carcinoma of the cervic uteri, basal or squamous cell carcinoma of the skin); no uncontrolled infection or other serious medical contidions; informed consent according to institutional guidelines. Pregnant or lactating females were not eligible for this study. Specific additional entry criteria for breast cancer patients were: not more than one prior chemotherapy regimen for advanced disease; discontinuation of chemotherapy or hormonal or radiation therapy at least 4 weeks before study entry (6 weeks in the case of prior mitomycin C or nitrosoureas. Specific additional entry criteria for melanoma patients were: no prior chemotherapy (exception adjuvant, local/extracorporal chemotherapy); prior immunotherapy with interleukin 2, interferon or other biological response modifiers was allowed. (Table II) . One event of grade 4 thrombocytopenia was unrelated to treatment. This patient subsequently developed disease-related disseminated intravascular coagulation syndrome. Another event of grade 4 thrombocytopenia was considered treatment-related. Non-haematological toxicities are summarised in Table III . Alopecia was complete and almost universal after two courses of treatment. Nausea and vomiting were infrequent and mild.
Response
Of 19 patients entered into the breast cancer study, two were considered not evaluable for response and two not eligible. However, of these, one patient showed a partial reponse after the first treatment but had to be taken off the study owing to grade 3 skin toxicity, including a bullous exanthema involving the trunk, neck and arms. The patient received further treatment with the CMF regimen. A second patient was inevaluable for response due to early death. One patient had a partial response after six courses but was found to be progressive 6 weeks later. This patient was classified as having an overall response of 'no change'. Six additional patients were classified as 'no change' (median duration 12 weeks, range 12-16+ weeks) and eight patients had progressive disease. Therefore no formal objective remissions (95% CI: 0-22%) were seen in the 15 evaluable patients.
In the melanoma study, two patients were not evaluable for response, both were lost to follow-up after one and two cycles respectively. Four patients had 'no change' (median duration 12 weeks, range 6-36 weeks). Twenty patients were (Bissett et al., 1992) . Of interest is, however, that both patients in the current studies had not received extensive prior treatment. One patient had achieved a partial response after four cycles of CMF 38 months before receiving rhizoxin. The other patient had only received hormonal and radiation therapy. All patients with 'no change' after rhizoxin had received prior anthrycyclinecontaining regimens. Also, 9 of 12 patients with progressive disease after rhizoxin had received prior anthracyclinecontaining regimens. These data indicate that chemonaive patients may be more sensitive to rhizoxin than pretreated patients and that further studies in minimally pretreated 399 patients may be warranted. In the melanoma study no objective remissions or even short-lasting tumour regressions were noted. This indicates that rhizoxin is inactive against this tumour type, despite its activity in preclinical melanoma models. Similar results were obtained in phase II trials conducted by CRC in colon, renal and ovarian cancer (Kerr et al., 1995) . Further studies of this class of agents will depend on the identification of more effective analogues in preclinical models.
Haematological toxicities during these phase II studies were acceptable. The leading side-effect was neutropenia, which was accompanied by fever of unknown origin and infection in a total of four patients. In accordance with the observation of a previous phase I study, non-haematological toxicities mainly consisted of stomatitis and asthenia. However, a variety of other, less severe toxicities were causally related to treatment with rhizoxin, including alopecia, skin reactions, local phlebitis at the site of injection and gastrointestinal symptoms.
We conclude that the administration of rhizoxin at 2.0 mg m-2 as intravenous bolus every 3 weeks is feasible and safe. However, clinical activity of this agent against advanced breast cancer is lacking. In addition, rhizoxin is clinically inactive against advanced melanoma.
